Whole genome sequencingWhole genome sequencing (WGS), also known as full genome sequencing, complete genome sequencing, or entire genome sequencing, is the process of determining the entirety, or nearly the entirety, of the DNA sequence of an organism's genome at a single time. This entails sequencing all of an organism's chromosomal DNA as well as DNA contained in the mitochondria and, for plants, in the chloroplast. Whole genome sequencing has largely been used as a research tool, but was being introduced to clinics in 2014.
Sanger sequencingSanger sequencing is a method of DNA sequencing that involves electrophoresis and is based on the random incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication. After first being developed by Frederick Sanger and colleagues in 1977, it became the most widely used sequencing method for approximately 40 years. It was first commercialized by Applied Biosystems in 1986. More recently, higher volume Sanger sequencing has been replaced by next generation sequencing methods, especially for large-scale, automated genome analyses.
Médecine personnaliséeLa médecine personnalisée est une médecine cherchant à améliorer la stratification et la prise en charge des patients en utilisant des informations biologiques et des biomarqueurs au niveau des voies moléculaires des maladies, de la génétique, de la protéomique ainsi que de la métabolomique. La définition de la médecine personnalisée n’a pas été véritablement établie et est parfois floue.
Exome sequencingExome sequencing, also known as whole exome sequencing (WES), is a genomic technique for sequencing all of the protein-coding regions of genes in a genome (known as the exome). It consists of two steps: the first step is to select only the subset of DNA that encodes proteins. These regions are known as exons—humans have about 180,000 exons, constituting about 1% of the human genome, or approximately 30 million base pairs. The second step is to sequence the exonic DNA using any high-throughput DNA sequencing technology.
Massive parallel sequencingMassive parallel sequencing or massively parallel sequencing is any of several high-throughput approaches to DNA sequencing using the concept of massively parallel processing; it is also called next-generation sequencing (NGS) or second-generation sequencing. Some of these technologies emerged between 1993 and 1998 and have been commercially available since 2005. These technologies use miniaturized and parallelized platforms for sequencing of 1 million to 43 billion short reads (50 to 400 bases each) per instrument run.
Third-generation sequencingThird-generation sequencing (also known as long-read sequencing) is a class of DNA sequencing methods currently under active development. Third generation sequencing technologies have the capability to produce substantially longer reads than second generation sequencing, also known as next-generation sequencing. Such an advantage has critical implications for both genome science and the study of biology in general. However, third generation sequencing data have much higher error rates than previous technologies, which can complicate downstream genome assembly and analysis of the resulting data.
Séquençage de l'ADNcadre|Résultat du séquençage par la méthode de Sanger. L'ordre de chaque bande indique la position d'un nucléotide A,T,C ou G Le séquençage de l'ADN consiste à déterminer l'ordre d'enchaînement des nucléotides pour un fragment d’ADN donné. La séquence d’ADN contient l’information nécessaire aux êtres vivants pour survivre et se reproduire. Déterminer cette séquence est donc utile aussi bien pour les recherches visant à savoir comment vivent les organismes que pour des sujets appliqués.
Polymorphisme nucléotidiquevignette|La molécule d'ADN 1 diffère de la 2 par un seul nucléotide (polymorphisme C/T). Le polymorphisme nucléotidique (PN, ou polymorphisme d'un seul nucléotide, PSN ; single nucleotide polymorphism, SNP) est, en génétique, la variation (polymorphisme) d'une seule paire de bases du génome entre individus d'une même espèce, ou entre un individu et la séquence de référence de l'espèce. La variation doit être située à un endroit spécifique du génome et apparaître sur une proportion supérieure à 1 % de la population pour être caractérisée comme PSN.
